Venetoclax Monotherapy Yields Deep Responses, Manageable Safety in CLL


Arnon P. Kater, MD, PhD, Professor of Hematology, Amsterdam University Medical Center, the Netherlands, discusses results from the phase 3b VENICE I trial, which evaluated the efficacy of venetoclax monotherapy in patients with relapsed/refractory CLL. These results were presented at the virtual 2020 EHA Annual Congress.

3 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Stay in the know.
OncNet Newsletter